NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE5942.65-16.45 (-0.28 %)
PREV CLOSE ( ) 5959.10
OPEN PRICE ( ) 5960.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 26331
TODAY'S LOW / HIGH ( )5881.15 5970.00
52 WK LOW / HIGH ( )4383.4 6505.5
NSE5942.85-14.3 (-0.24 %)
PREV CLOSE( ) 5957.15
OPEN PRICE ( ) 6000.00
BID PRICE (QTY) 5942.85 (2)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 342651
TODAY'S LOW / HIGH( ) 5880.80 6000.00
52 WK LOW / HIGH ( )4384.05 6505.9
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 24-02 1984
Management Info
K Satish Reddy - Chairman GV Prasad - Managing Director
Registered Office

Address 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 - 4900 2900

Email mail@drreddys.com / shares@drreddys.com

Website www.drreddys.com

Registrars Details
Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
 Listing : BSE, NSE, MCX, New York
NEWS
19Apr Dr.Reddy's Laboratories submits certif
Dr.Reddy's Laboratories has submitted Certificate Under Regulation 40(9)..
15Apr Dr. Reddy’s Laboratories’ arm to sell
Dr. Reddy’s Laboratories’ wholly owned subsidiary -- Dr. Reddy’s Laborat..
10Apr Dr. Reddy’s launches drug-free migrain
Dr. Reddy’s Laboratories has launched the drug-free non-invasive migrain..
05Apr Dr. Reddy's, Bayer sign marketing, dis
Dr. Reddy's Laboratories and Bayer have entered into a partnership to ma..
28Mar Dr. Reddy's Laboratories enters into e
Dr. Reddy's Laboratories has entered into an exclusive partnership with..
MORE
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit475226128
Gross Profit 6319 38660
Operating Profit 883948061
Net Sales 41030169625
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Bharat Parenterals (BSE)
 1455.20 (10.00%)
M.Cap (Rs. in Cr)846.88
Solara Active Pharma (BSE)
 551.45 (16.32%)
M.Cap (Rs. in Cr)1985.01
Abbott India (BSE)
 26131.85 (0.29%)
M.Cap (Rs. in Cr)55528.36
Windlas Biotech (BSE)
 555.05 (6.97%)
M.Cap (Rs. in Cr)1154.42
Concord Biotech (BSE)
 1595.25 (1.05%)
M.Cap (Rs. in Cr)16688.90
MORE
Shareholding Pattern
PROMOTERS 26.65%
NON-INSTITUTION 10.55%
MUTUAL FUNDS/UTI 7.96%
FI/BANKS/INSURANCE 7.79%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.